Search results
Thank You for Listening to Whatever It Is They Do! | News Radio 103.1 and 810 WGY | Joe Gallagher
iHeartRadio· 5 days agoOn behalf of Joe & Zach, I want to thank you for listening to their weekend morning show airing on...
Allan Sherman - Funny Halloween Songs | iHeart
iHeartRadio· 2 days agoBla Bla Bla Bla Says Dracula (Funny Halloween Song), Funny Halloween Song, Each Time You Kiss Me (Funny Halloween Song)
Sarah Jessica Parker Just Gave Us The Chicest ‘And Just Like That’ Season 3 Update
PureWow via Yahoo News· 3 days agoIn a carousel shared on the actress's Instagram account on Wednesday, the Sex and the City star...
What's Going On With Novavax Stock Thursday? - Novavax (NASDAQ:NVAX)
Benzinga· 3 days agoNovavax Inc NVAX shares are trading higher Thursday after the U.S. Food and Drug Administration's...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 days agoTelix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and reminds ...
On their way to LA
Citrus Chronicle Online· 6 days agoThe Beyond Limits Athletics (BLA) Elite flag football team out of Citrus County just keeps adding to its impressive list of accolades.
Hansa completes randomisation in Phase III trial of imlifidase
Clinical Trials Arena via Yahoo Finance· 6 days agoThe trial data is a pivotal step towards submitting a biologic licence application (BLA) to the US...
GRIT and Quangang announce IL-2 T-cell therapy partnership
Pharmaceutical Technology via Yahoo Finance· 6 days ago-cell treatments, along with an affordable local IL-2 product. GRIT’s non-gene-engineered tumour...
BMO holds Replimune stock on positive trial momentum By Investing.com
Investing.com· 2 days agoOn Friday, BMO Capital maintained its Outperform rating and $14.00 price target for Replimune Group...
